5-amino-N,N-dimethylpicolinamide | 1206641-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-amino-N,N-dimethylpicolinamide
• 英文别名: N,N-dimethyl-5-aminopyridine-2-carboxamide；5-amino-N,N-dimethylpyridine-2-carboxamide
• CAS: 1206641-29-3
• 化学式: C₈H₁₁N₃O
• 分子量: 165.195
• InChiKey: YHBUXVGUIWRTNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三光气 、 5-amino-N,N-dimethylpicolinamide 、 (S)-1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-amine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以45 %的产率得到(S)-5-(3-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)ureido)-N,N-dimethylpicolinamide
  参考文献：
  名称：

  [EN] UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER
  [FR] DÉRIVÉS D'URÉE POUVANT ÊTRE UTILISÉS POUR TRAITER LE CANCER

  摘要：

  This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2022265993A1
• 作为产物：
  描述：

  tert-butyl N-[6-(dimethylcarbamoyl)pyridin-3-yl]carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 5-amino-N,N-dimethylpicolinamide
  参考文献：
  名称：

  [EN] PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS INHIBITEURS DE PYRIMIDINE TBK/IKKε ET LEURS UTILISATIONS

  摘要：

  这项发明涉及公式I的化合物及其药用可接受的组合物，可用作TBK/IKKε抑制剂。

  公开号：

  WO2019079373A1

文献信息

• [EN] [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS<br/>[FR] [1, 2, 4]TRIAZOLO[1, 5-A]PYRIDINES UTILISÉES COMME INHIBITEURS DE JAK
  申请人：GALAPAGOS NV

  公开号：WO2010010184A1

  公开（公告）日：2010-01-28

  Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.

  揭示了一种具有以下式表示的化学式的新型[1,2,4]三唑并[1,5-a]吡啶化合物（I）。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如关节疾病、炎症等。
• NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2390254A1

  公开（公告）日：2011-11-30

  Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group represented by formula: -NH-, or the like; ring A represents a 6-membered aromatic ring which may contain 1 to 2 nitrogen atoms as heteroatoms (the aromatic ring may be substituted by a halogen atom, a group represented by formula: -CONRaRb, or the like; Ra and Rb are the same or different and independently represent hydrogen, alkyl, hydroxyalkyl, or the like); R1 represents an acyl group or the like; and R2 represents a halogen atom or a cyano group.

  揭示了一种新型吡咯并[2,3-d]嘧啶化合物，其表示为式[I]或其药理学上可接受的盐，具有GPR119受体激动活性，并且对制药有用。在式[I]中，E代表由式表示的基团：-NH-，或类似基团；环A代表可能含有1至2个氮原子作为杂原子的6元芳香环（芳香环可能被卤素原子、由式表示的基团：-CONRaRb，或类似基团取代；Ra和Rb相同或不同且独立地代表氢、烷基、羟基烷基，或类似基团）；R1代表酰基团或类似基团；R2代表卤素原子或氰基。
• NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
  申请人：Tsuboi Yasunori

  公开号：US20120016119A1

  公开（公告）日：2012-01-19

  Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group represented by formula: —NH—, or the like; ring A represents a 6-membered aromatic ring which may contain 1 to 2 nitrogen atoms as heteroatoms (the aromatic ring may be substituted by a halogen atom, a group represented by formula: —CONR a R b , or the like; R a and R b are the same or different and independently represent hydrogen, alkyl, hydroxyalkyl, or the like); R 1 represents an acyl group or the like; and R 2 represents a halogen atom or a cyano group.

  本发明公开了一种新型吡咯并[2,3-d]嘧啶化合物，其化学式为[I]或其药学上可接受的盐，具有GPR119受体激动活性，可用于制药。在式[I]中，E代表化学式表示的基团：—NH—或类似基团；环A代表一个6元芳环，其中可含有1至2个氮原子作为杂原子（芳环可被卤素原子、化学式表示的基团：—CONRaRb或类似基团取代；Ra和Rb相同或不同且独立地代表氢、烷基、羟基烷基或类似基团）；R1代表酰基基团或类似基团；R2代表卤素原子或氰基。
• VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF
  申请人：Salahieh Amr

  公开号：US20110257678A1

  公开（公告）日：2011-10-20

  Vascular embolic filtering systems, as well as methods for using the same, are provided. In general, the subject invention includes a system comprised of a delivery and retrieval sheath adapted for delivering and retrieving multiple embolic filters, wherein the embolic filters are each operatively coupled to a distal region of a filter wire segment and are deployable within a target vessel.
• [EN] PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE PYRIMIDINE TBK/IKKε ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019079373A1

  公开（公告）日：2019-04-25

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  这项发明涉及公式I的化合物及其药用可接受的组合物，可用作TBK/IKKε抑制剂。